In the original article “Fürst and Zündoft, 2014” was not cited in the article. The citation has now been inserted in section Immunomodulators, Paragraph 3 and should read:
“Recently the clinical potential of six plant-derived anti-inflammatory compounds: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate (EGCG), and quercetin has been highlighted Fürst and Zündoft (2014). The present review will give an overview of these widely investigated plant-derived compounds including andrographolide and genistein, which have exhibited potent effects on cellular and humoral immune functions in pre-clinical investigations and will highlight their clinical potential.”
The citation has now been inserted in section Curcumin, Paragraph 2 and should read:
“However, Fürst and Zündoft (2014) suggested that these are preliminary clinical trials which are frequently too weak and of low quality to draw a conclusion due to the low number of enrolled patients, which normally ranges from 10 to 30. As suggested by the authors, more operationally thorough and serious randomized controlled trials are required to evaluate the compound as an effective and safe agent for human use. It is worth mentioning that curcumin suffers from its low bioavailability, though substantial improvement has been made to address this issue via chemical and technological methods (Anand et al., 2007).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
The original article has been updated.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AnandP.KunnumakkaraA. B.NewmanR. A.AggarwalB. B. (2007). Bioavailability of curcumin: problems and promises. Mol. Pharm.4, 807–818. 10.1021/mp700113r
2
FürstR.ZündoftI. (2014). Plant-derived anti-inflammatory compounds: Hopes and dissapointments regarding the translation of preclinical knowledge into clinical progress. Mediat. Inflamm.2014:146832. 10.1155/2014/146832
Summary
Keywords
immunomodulation, curcumin, resveratrol, epigallocatechol-3-gallate, quercetin, colchicine, capsaicin
Citation
Jantan I, Ahmad W and Bukhari SNA (2018) Corrigendum: Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials. Front. Plant Sci. 9:1178. doi: 10.3389/fpls.2018.01178
Received
16 July 2018
Accepted
23 July 2018
Published
13 August 2018
Approved by
Frontiers in Plant Science, Frontiers Media SA, Switzerland
Volume
9 - 2018
Updates
Copyright
© 2018 Jantan, Ahmad and Bukhari.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ibrahim Jantan profibj@gmail.com
This article was submitted to Plant Metabolism and Chemodiversity, a section of the journal Frontiers in Plant Science
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.